{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,3,28]],"date-time":"2022-03-28T23:46:58Z","timestamp":1648511218504},"reference-count":35,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2014,6,1]],"date-time":"2014-06-01T00:00:00Z","timestamp":1401580800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Seminars in Pediatric Neurology"],"published-print":{"date-parts":[[2014,6]]},"DOI":"10.1016\/j.spen.2014.04.023","type":"journal-article","created":{"date-parts":[[2014,4,24]],"date-time":"2014-04-24T08:53:19Z","timestamp":1398329599000},"page":"145-151","source":"Crossref","is-referenced-by-count":0,"title":["Unilateral Visual Loss in a Previously Healthy 15-Year-Old Girl: Monosymptomatic Neuromyelitis Optica?"],"prefix":"10.1016","volume":"21","author":[{"given":"John F.","family":"Kerrigan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christina","family":"Chrisman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reena Gogia","family":"Rastogi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.spen.2014.04.023_bib1","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1212\/WNL.45.2.244","article-title":"Optic neuritis: A population-based study in Olmstead county, Minnesota","volume":"45","author":"Rodriguez","year":"1995","journal-title":"Neurology"},{"key":"10.1016\/j.spen.2014.04.023_bib2","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.jaapos.2011.05.020","article-title":"Pediatric optic neuritis and risk of multiple sclerosis: Meta-analysis of observational studies","volume":"15","author":"Waldman","year":"2011","journal-title":"J AAPOS"},{"key":"10.1016\/j.spen.2014.04.023_bib3","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/S0002-9394(98)00152-4","article-title":"Relative afferent pupillary defects in patients with Leber hereditary optic neuropathy and unilateral visual loss","volume":"126","author":"Jacobson","year":"1998","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.spen.2014.04.023_bib4","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/S0021-5155(98)00072-0","article-title":"Baseline features of idiopathic optic neuritis as determined by a multicenter treatment trial in Japan. Optic Neuritis Treatment Trial Multicenter Cooperative Research Group (ONMRG)","volume":"43","author":"Wakakura","year":"1999","journal-title":"Jpn J Ophthalmol"},{"key":"10.1016\/j.spen.2014.04.023_bib5","doi-asserted-by":"crossref","DOI":"10.1177\/0284185112471797","article-title":"Accuracy of routine fat-suppressed FLAIR and diffusion-weighted images in detecting clinically evident optic neuritis","author":"McKinney","year":"2013","journal-title":"Acta Radiol"},{"key":"10.1016\/j.spen.2014.04.023_bib6","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1212\/01.wnl.0000224757.69746.fb","article-title":"The clinical features, MRI findings, and outcome of optic neuritis in children","volume":"67","author":"Wilejto","year":"2006","journal-title":"Neurology"},{"key":"10.1016\/j.spen.2014.04.023_bib7","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1212\/WNL.0b013e3181af78b8","article-title":"Optical coherence tomography helps differentiate neuromyelitis optica and MS optic neuropathies","volume":"73","author":"Ratchford","year":"2009","journal-title":"Neurology"},{"key":"10.1016\/j.spen.2014.04.023_bib8","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/0165-5728(94)90175-9","article-title":"Optic neuritis is associated with myelin basic protein and proteolipid protein reactive cells producing interferon-gamma, interleukin-4 and transforming growth factor-beta","volume":"49","author":"Link","year":"1994","journal-title":"J Neuroimmunol"},{"key":"10.1016\/j.spen.2014.04.023_bib9","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1212\/WNL.43.6.1215","article-title":"Optic neuritis and multiple sclerosis: Anti-MBP and anti-MBP peptide antibody-secreting cells are accumulated in CSF","volume":"43","author":"Soderstrom","year":"1993","journal-title":"Neurology"},{"key":"10.1016\/j.spen.2014.04.023_bib10","doi-asserted-by":"crossref","first-page":"6964","DOI":"10.1167\/iovs.12-10559","article-title":"Visual functional and histopathological correlation in experimental autoimmune optic neuritis","volume":"53","author":"Matsunaga","year":"2012","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.spen.2014.04.023_bib11","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1001\/archopht.121.7.944","article-title":"High- and low-risk profiles for the development of multiple sclerosis within 10 years after optic neuritis: Experience of the optic neuritis treatment trial","volume":"121","author":"Beck","year":"2003","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.spen.2014.04.023_bib12","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1016\/j.ophtha.2007.08.004","article-title":"Visual function 15 years after optic neuritis: A final follow-up report from the optic neuritis treatment trial","volume":"115","year":"2008","journal-title":"Ophthalmology"},{"key":"10.1016\/j.spen.2014.04.023_bib13","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1212\/WNL.54.11.2039","article-title":"Practice parameter: The role of corticosteroids in the management of acute monosymptomatic optic neuritis: Report of the Quality Standards Subcommittee of the American Academy of Neurology","volume":"54","author":"Kaufman","year":"2000","journal-title":"Neurology"},{"key":"10.1016\/j.spen.2014.04.023_bib14","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1212\/01.wnl.0000344163.65326.48","article-title":"Pediatric optic neuritis: Brain MRI abnormalities and risk of multiple sclerosis","volume":"72","author":"Bonhomme","year":"2009","journal-title":"Neurology"},{"key":"10.1016\/j.spen.2014.04.023_bib15","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1056\/NEJMcp053247","article-title":"Optic neuritis","volume":"354","author":"Balcer","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.spen.2014.04.023_bib16","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1111\/ene.12327","article-title":"Clinical presentation of pediatric multiple sclerosis before puberty","volume":"21","author":"Huppke","year":"2014","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.spen.2014.04.023_bib17","doi-asserted-by":"crossref","first-page":"S7","DOI":"10.1212\/01.wnl.0000259422.44235.a8","article-title":"Consensus definitions proposed for pediatric multiple sclerosis and related disorders","volume":"68","author":"Krupp","year":"2007","journal-title":"Neurology"},{"key":"10.1016\/j.spen.2014.04.023_bib18","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1177\/1352458513484547","article-title":"International pediatric multiple sclerosis study group criteria for pediatric multiple sclerosis and immune-mediated central nervous system demyelinating disorders: Revisions to the 2007 definitions","volume":"19","author":"Krupp","year":"2013","journal-title":"Mult Scler J"},{"key":"10.1016\/j.spen.2014.04.023_bib19","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1084\/jem.20050304","article-title":"IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel","volume":"202","author":"Lennon","year":"2005","journal-title":"J Exp Med"},{"key":"10.1016\/j.spen.2014.04.023_bib20","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1212\/01.wnl.0000216139.44259.74","article-title":"Revised diagnostic criteria for neuromyelitis optica","volume":"66","author":"Wingerchuk","year":"2006","journal-title":"Neurology"},{"key":"10.1016\/j.spen.2014.04.023_bib21","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/S1474-4422(07)70216-8","article-title":"The spectrum of neuromyelitis optica","volume":"6","author":"Wingerchuk","year":"2007","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.spen.2014.04.023_bib22","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1001\/archneur.63.3.390","article-title":"Brain abnormalities in neuromyelitis optica","volume":"63","author":"Pittock","year":"2006","journal-title":"Arch Neurol"},{"key":"10.1016\/j.spen.2014.04.023_bib23","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1038\/nrneurol.2010.72","article-title":"AQP4 antibodies in neuromyelitis optica: Diagnostic and pathogenetic relevance","volume":"6","author":"Jarius","year":"2010","journal-title":"Nat Rev Neurol"},{"key":"10.1016\/j.spen.2014.04.023_bib24","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1093\/brain\/awp309","article-title":"Intra-cerebral injection of neuromyelitis optica immunoglobulin G and human complement produces neuromyelitis optica in mice","volume":"133","author":"Saadoun","year":"2010","journal-title":"Brain"},{"key":"10.1016\/j.spen.2014.04.023_bib25","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1002\/ana.22551","article-title":"Ex vivo spinal cord slice model of neuromyelitis optica reveals novel immunopathogenic mechanisms","volume":"70","author":"Zhang","year":"2011","journal-title":"Ann Neurol"},{"key":"10.1016\/j.spen.2014.04.023_bib26","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/S1474-4422(12)70133-3","article-title":"Aquaporin 4 and neuromyelitis optica","volume":"11","author":"Papadopoulos","year":"2012","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.spen.2014.04.023_bib27","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1002\/ana.22657","article-title":"Anti-aquaporin-4 monoclonal antibody blocker therapy for neuromyelitis optica","volume":"71","author":"Tradtrantip","year":"2012","journal-title":"Ann Neurol"},{"key":"10.1016\/j.spen.2014.04.023_bib28","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1177\/1756285611398939","article-title":"Current and future treatment approaches for neuromyelitis optica","volume":"4","author":"Collongues","year":"2011","journal-title":"Ther Adv Neurol Disord"},{"key":"10.1016\/j.spen.2014.04.023_bib29","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1001\/jamaneurol.2013.3583","article-title":"Individualized rituximab treatment for neuromyelitis optica spectrum disorders","volume":"70","author":"McKeon","year":"2013","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.spen.2014.04.023_bib30","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1001\/jamaneurol.2013.5699","article-title":"Comparison of relapse and treatment failure rates among patients with neuromyelitis optica; multicenter study treatment efficacy","volume":"71","author":"Mealy","year":"2014","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.spen.2014.04.023_bib31","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1001\/archneur.65.11.noc80069","article-title":"Treatment of neuromyelitis optica with rituximab: retrospective analysis of 25 patients","volume":"65","author":"Jacob","year":"2008","journal-title":"Arch Neurol"},{"key":"10.1016\/j.spen.2014.04.023_bib32","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1001\/jamaneurol.2013.3071","article-title":"A 5-year follow-up of rituximab treatment in patients with neuromyelitis optica spectrum disorder","volume":"70","author":"Kim","year":"2013","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.spen.2014.04.023_bib33","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/s11940-011-0159-0","article-title":"Treatment of pediatric optic neuritis","volume":"14","author":"Bonhomme","year":"2012","journal-title":"Curr Treat Options Neurol"},{"key":"10.1016\/j.spen.2014.04.023_bib34","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1177\/0883073810381445","article-title":"Efficacy and safety of rituximab in pediatric neuromyelitis optica","volume":"26","author":"Mahmood","year":"2011","journal-title":"J Child Neurol"},{"key":"10.1016\/j.spen.2014.04.023_bib35","doi-asserted-by":"crossref","first-page":"2210","DOI":"10.1212\/WNL.0b013e318296ea08","article-title":"Aquaporin-4 antibody-positive cases beyond current diagnostic criteria for NMO spectrum disorders","volume":"80","author":"Sato","year":"2013","journal-title":"Neurology"}],"container-title":["Seminars in Pediatric Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1071909114000424?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1071909114000424?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,4]],"date-time":"2018-10-04T17:58:33Z","timestamp":1538675913000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1071909114000424"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,6]]},"references-count":35,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014,6]]}},"alternative-id":["S1071909114000424"],"URL":"https:\/\/doi.org\/10.1016\/j.spen.2014.04.023","relation":{},"ISSN":["1071-9091"],"issn-type":[{"value":"1071-9091","type":"print"}],"subject":[],"published":{"date-parts":[[2014,6]]}}}